Atika Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Atika Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,000	Closed	-$19.8M	–	82
2025 Q4	$19.8M	Buy	+34,000	New	+$17.4M	2.08%	9
2018 Q4	–	Sell	-14,000	Closed	-$2.17M	–	89
2018 Q3	$3M	Sell	14,000 -12,499	-47%	-$3.14M	0.54%	65
2018 Q2	$7.41M	Buy	26,499 +8,499	+47%	+$1.49M	1.43%	19
2018 Q1	$2.1M	Buy	+18,000	New	+$2.22M	0.72%	53

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Atika Capital Management's MDGL Position: Q1 2026 in Review

Atika Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 34,000 shares — an estimated $19.8M sold.

Atika Capital Management first reported a position in MDGL in Q1 2018 and held it in 4 quarters. The position peaked at $19.8M in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Atika Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Atika Capital Management sold 34,000 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $19.8M.
Atika Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Atika Capital Management's Madrigal Pharmaceuticals position peaked at $19.8M in Q4 2025.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.